Holen Sie sich die Stockscreener-App
29.44
2.15%
0.62
Handel nachbörslich:
29.44
Damora Therapeutics Inc Aktie (DMRA) Neueste Nachrichten
DMRA Initiates Coverage On Jefferies -- Rating Set to Buy, PT at $50 - GuruFocus
H.C. Wainwright reiterates Damora Therapeutics stock rating on device advantage - Investing.com Canada
This Damora Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Jefferies initiates Damora Therapeutics stock with buy rating By Investing.com - Investing.com Canada
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
Damora Therapeutics, Inc. Revenue Breakdown – NASDAQ:DMRA - TradingView
Damora Therapeutics, Inc. Common Stock (DMRA) Institutional Ownership 2026 - MarketBeat
Damora Therapeutics (DMRA) AGM 2026 Summary - Quartr
Damora Therapeutics (DMRA) Proxy filing Summary - Quartr
symbol__ Stock Quote Price and Forecast - CNN
DMRA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus
H.C. Wainwright reiterates Buy on Damora Therapeutics stock By Investing.com - Investing.com Canada
Damora Therapeutics Completes Cayman Islands Redomestication - TipRanks
Damora Therapeutics completes redomestication to Cayman Islands - Investing.com
Damora Announces Redomestication from Delaware to Cayman Islands - The Manila Times
Damora Will Keep DMRA Ticker Under New Nasdaq CUSIP July 20 - Stock Titan
Damora Therapeutics Inc. (DMRA) Q1 2026 Earnings: Wider-than-Expected Loss on Pre-Revenue Pipeline Progress - dars.gov.et
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Chart and Price History 2026 - MarketBeat
Damora Therapeutics, Inc. Common Stock (DMRA) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
Damora Therapeutics Q1 2026 Earnings: Wider-than-Expected Loss Sends Shares LowerGeographic Revenue Trends - dars.gov.et
Is Broad Russell Index Inclusion Altering The Investment Case For Damora Therapeutics (DMRA)? - simplywall.st
Damora Therapeutics (DMRA) Sheds Over 6%: Support Levels in Focus After Sharp DeclineDealer Delta - dars.gov.et
Form 4 Damora Therapeutics Inc For: 7 July By Investing.com - Investing.com South Africa
Damora Therapeutics general counsel sells $7,345 in stock By Investing.com - Investing.com Nigeria
Damora Therapeutics general counsel sells $7,345 in stock - Investing.com
[Form 4] Damora Therapeutics, Inc. Insider Trading Activity - Stock Titan
Price to earnings forward of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
Price to sales forward of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Damora awards 453,500 stock options to nine new hires - Stock Titan
RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Damora Therapeutics, Inc.(NasdaqCM:DMRA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 2500 Growth Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 2000 Index - marketscreener.com
Damora Therapeutics (DMRA) Is Up 6.2% After Broad Russell Index Additions Has The Bull Case Changed? - simplywall.st
Damora Therapeutics, Inc. Actuals & Estimates (NASDAQ:DMRA) - TradingView
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 2000 Value Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 2000 Growth Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 3000E Growth Benchmark - marketscreener.com
Damora Therapeutics (DMRA) Slides 4.5%: Key Support Levels in FocusGamma Flip Level - DonanımHaber
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 3000 Value Benchmark - marketscreener.com
Damora Therapeutics Rises as Traders Focus on Near-Term Pipeline Catalysts - Quiver Quantitative
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):